Who is sponsoring NCT00998881?

NCT00998881 is sponsored by Tanabe Pharma Corporation.

What condition does NCT00998881 study?

NCT00998881 studies Type 2 Diabetes Mellitus.

What drugs are being tested in NCT00998881?

Interventions: Teneligliptin 20 mg, Placebo.

What is the status of NCT00998881?

NCT00998881 is currently COMPLETED.

Last reviewed 2025-12-15 · How we verify

A Phase III, Double-blind, Placebo Controlled, Monotherapy Study of MP-513 in Japanese Patients With Type 2 Diabetes Mellitus - Confirmative Study

NCT00998881 Phase 3 COMPLETED Results posted

The purpose of this study is to evaluate the efficacy and safety of MP-513 (Teneligliptin) in patients with type 2 Diabetes for 12 weeks administration.

Details

Lead sponsor	Tanabe Pharma Corporation
Phase	Phase 3
Status	COMPLETED
Enrolment	203
Start date	2009-09
Completion	2010-06

Conditions

Type 2 Diabetes Mellitus

Interventions

Teneligliptin 20 mg
Placebo

Primary outcomes

Change From Baseline in HbA1c at Week 12 — 12 weeks
The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline HbA1c as a covariate.

Countries

Japan